Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterizing the metabolomes of microglia, astrocytes, and neurons in the brain across states of health, aging, and disease

ABSTRACT: Neurons and glia are distinct in their morphology, development, and function. They have unique transcriptomes and proteomes, but little is known about their metabolomes. The challenge of brain cell metabolic profiling is to obtain a large number of pure cells for reliable analysis. Here, we purify microglia, astrocytes, and neurons from the genetically labeled-brain. We identified >70 metabolites in them with targeted metabolomics and 9,854 metabolite features with untargeted metabolomics. We systematically characterized cell type–enriched metabolites and metabolic pathways. The enrichment of glutathione (GSH) metabolism in microglia was further validated in vivo. A significant decrease in GSH levels and GSH metabolism observed in microglia in aging and Alzheimer's disease (AD) models. Disrupting GSH metabolism in microglia results in aberrant morphogenesis, upregulation of mitophagy-related genes, and the deposition of β-Amyloid. Our results provide a valuable resource for metabolic studies related to aging, AD and other neurological diseases.

ORGANISM(S): Mus musculus

PROVIDER: GSE316928 | GEO | 2026/02/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Global Stable-isotope Tracing Metabolomics Reveals System-wide Metabolic Alternations in Aging Drosophila

Project description:System-wide metabolic homeostasis is crucial for maintaining physiological functions of living organisms. Stable-isotope tracing metabolomics allows to unravel metabolic activity quantitatively by measuring the isotopically labeled metabolites, but has been largely restricted by coverage. Yet, delineating system-wide metabolic homeostasis at the whole-organism level remains non-trivial. Here, we develop a global isotope tracing metabolomics technology to measure labeled metabolites with a metabolome-wide coverage. Using Drosophila as an aging model organism, we probe the in vivo tracing kinetics with quantitative information on labeling patterns, extents and rates on a metabolome-wide scale. We curate a system-wide metabolic network to characterize metabolic homeostasis and disclose a system-wide loss of metabolic coordinations that impacts both intra- and inter-tissue metabolic homeostasis significantly during Drosophila aging. Importantly, we reveal an unappreciated metabolic diversion from glycolysis to serine metabolism and purine metabolism as Drosophila aging. The developed technology facilitates a system-level understanding of metabolic regulation in living organisms.

2022-05-29 | GSE204740 | GEO

Puri2010 - Mathematical Modeling for the Pathogenesis of Alzheimer's Disease

Project description:Puri2010 - Mathematical Modeling for the Pathogenesis of Alzheimer's Disease Puri2010 - Mathematical Modeling for the Pathogenesis of Alzheimer's Disease Encoded non-curated model. Issues: - Confusing replacement of α16 when t = 3 years - Confusing 4th rate equation This model is described in the article: Mathematical modeling for the pathogenesis of Alzheimer's disease. Puri IK, Li L. PLoS ONE 2010; 5(12): e15176 Abstract: Despite extensive research, the pathogenesis of neurodegenerative Alzheimer's disease (AD) still eludes our comprehension. This is largely due to complex and dynamic cross-talks that occur among multiple cell types throughout the aging process. We present a mathematical model that helps define critical components of AD pathogenesis based on differential rate equations that represent the known cross-talks involving microglia, astroglia, neurons, and amyloid-? (A?). We demonstrate that the inflammatory activation of microglia serves as a key node for progressive neurodegeneration. Our analysis reveals that targeting microglia may hold potential promise in the prevention and treatment of AD. This model is hosted on BioModels Database and identified by: MODEL1409240001. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

2015-04-15 | MODEL1409240001 | BioModels

Genome-scale metabolic modelling uncovers cell-type specific signatures associated with APOE variants

Project description:Metabolic dysregulation is a key feature of Alzheimer’s disease (AD) pathogenesis. The ε4 variant of APOE gene (APOE4), coding for the lipid-transporter apolipoprotein E, is the strongest genetic risk factor for late-onset AD. Previous studies have investigated how APOE4 disrupts specific metabolic pathways within different cell types. In this study, we followed a broad, metabolite-centric approach to investigate how APOE4 reshapes cellular metabolism in a cell type-specific manner based on transcriptome and metabolome data. We integrated transcriptomics data from an isogenic set of iPSC-derived neurons, astrocytes, and microglia harboring APOE3 or APOE4 genotypes into a human genome-scale metabolic model. From this model, we identified metabolic pathways that differed between APOE3 and APOE4 cells. We then used metabolomics data from the same iPSC-derived cell types to validate pathways identified by the transcriptomic analysis. In addition to confirming previous reports of disrupted cholesterol and fatty acid metabolism, we also identified bile acid biosynthesis, folate metabolism, and thyroid hormone metabolism as novel pathways dysregulated in APOE4 cells. Moreover, we were able to detect similar metabolic dysregulation in human post-mortem transcriptomic data. By integrating transcriptomic and metabolomic data, our approach can enhance understanding of biological mechanisms associated with APOE4-associated metabolic dysregulation in AD.

2026-03-17 | GSE305481 | GEO

Transcriptomic signatures of oxytosis/ferroptosis are enriched in Alzheimer’s disease

Project description:Oxytosis/ferroptosis is a non-apoptotic regulated cell death pathway characterized by glutathione (GSH) depletion with consequent inhibition of the GSH-dependent enzyme GSH peroxidase 4 (Gpx4), activation of lipoxygenases (LOXs), production of reactive oxygen species (ROS) and mitochondrial dysfunction, that culminates in cell death. Most of these changes are observed with aging and exacerbated in Alzheimer’s disease (AD). Furthermore, it has been shown that novel inhibitors of oxytosis/ferroptosis are protective in mouse models of aging and AD. One of the most potent of these inhibitors is the neuroprotective compound CMS121. The goal of the present study was to investigate the occurrence of oxytosis/ferroptosis in the AD brain by examining transcriptomic signatures of oxytosis/ferroptosis in multiple cellular and animal models of AD as well as in human AD brain samples. Our data show that different signatures of oxytosis/ferroptosis are enriched to varying extents in the brains of AD mice and human AD patients. https://doi.org/10.1186/s12915-025-02235-6

2025-01-06 | GSE278716 | GEO

The essential roles of FXR in diet and aging affected metabolic changes and liver disease development: a multi-omics study

Project description:Aging and unhealthy diets are risks for metabolic diseases including liver cancer. Bile acid receptor farnesoid X receptor (FXR) knockout (KO) mice develop metabolic liver diseases and progress into liver cancer as they age, and Western diet (WD) intake facilitates liver carcinogenesis in those mice. This study aimed to uncover molecular signatures within the gut-liver axis for diet and age-linked liver diseases in FXR-dependent or independent manners. Many more transcripts were changed due to WD intake and aging in WT mice than those in FXR KO mice. In other words, WD intake and aging impact the hepatic transcriptomes and metabolomes in an FXR-dependent manner. In WT mice, WD/aging upregulated inflammation-related genes and downregulated genes involved in oxidative phosphorylation (OXPHOS). Urine metabolomes provided clear distinguishing for differential dietary intake. By contrast, the metabolomes of the liver, serum, or urine could reflect age differences. Further, irrespective of differential diets intake or ages, transcriptomes, metabolomes, and cecal microbiota distinguished WT and FXR KO. Western dietary patterns and aging share molecular commonality with FXR deactivation. Notably, WD, aging, and FXR deactivation commonly altered hepatic cell division-related transcripts (Cenpe, Ect2, Top2a, Kif20a, Tpx2, Nuf2, Kif18b, Aspm, E2f8, and Hmmr), which are associated with overall survival rate in HCC patients. In conclusion, FXR is essential for maintaining metabolic homeostasis in response to WD intake and aging. FXR activation helps to alleviate diet and/or aging-induced metabolic health issues.

2023-02-22 | GSE216375 | GEO

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and -independent cellular responses in Alzheimer’s disease [7 months]

Project description:Glia have been implicated in Alzheimer’s disease (AD) pathogenesis. Variants of the microglia receptor TREM2 increase AD risk and activation of “disease-associated microglia” (DAM) is dependent on TREM2 in mouse models of AD. We surveyed gene expression changes associated with AD pathology and TREM2 in 5XFAD mice and human AD by snRNA-seq. We confirmed the presence of Trem2-dependent DAM and identified a novel Serpina3n+C4b+ reactive oligodendrocyte population in mice. Interestingly, remarkably different glial phenotypes were evident in human AD. Microglia signature was reminiscent of IRF8-driven reactive microglia in peripheral nerve injury. Oligodendrocyte signatures suggested impaired axonal myelination and metabolic adaptation to neuronal degeneration. Astrocyte profiles indicated weakened metabolic coordination with neurons. Notably, the reactive phenotype of microglia was less palpable in TREM2 R47H and R62H carriers than in non-carriers, demonstrating a TREM2 requirement in both mouse and human AD, despite the marked species-specific differences.

2019-12-31 | GSE140510 | GEO

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and -independent cellular responses in Alzheimer’s disease [15 months]

2019-12-31 | GSE140399 | GEO

Loss of insulin signaling in microglia impairs cellular uptake of Aβ and neuroinflammatory response exacerbating AD-like neuropathology

Project description:Insulin receptors are present on cells throughout the body, including the brain. Dysregulation of insulin signaling in neurons and astrocytes has been implicated in altered mood, cognition, and the pathogenesis of Alzheimer’s disease (AD). To define the role of insulin signaling in microglia, the primary phagocytes in brain critical for maintenance and damage repair, we created mice with an inducible microglia-specific insulin receptor knockout (MG-IRKO). RiboTag profiling of microglial mRNAs revealed that loss of insulin signaling results in alterations of gene expression in pathways related to innate immunity and cellular metabolism. In vitro, loss of insulin signaling in microglia results in metabolic reprograming with an increase in glycolysis and impaired uptake of Aβ. In vivo, MG-IRKO mice exhibit alterations in mood and social behavior, and when crossed with the 5xFAD mouse model of AD, the resultant mice exhibit increased levels of Aβ plaque and elevated neuroinflammation. Thus, insulin signaling in microglia plays a key role in microglial cellular metabolism and the ability of the cells to take up Aβ, such that reduced insulin signaling in microglia alters mood and social behavior and accelerates AD pathogenesis. Together these data indicate key roles of insulin action in microglia and the potential of targeting insulin signaling in microglia in treatment of AD.

2025-06-16 | GSE296386 | GEO

NAD+ - and EVA1-C-dependent reversal of neurological deficits is mediated by differential alternative RNA splicing in tauopathic animal models

Project description:Aberrant alternative splicing events (ASEs) are emerging as a new hallmark of aging and are linked to age-related neurodegenerative pathologies such as Alzheimer’s disease (AD). AD brains are characterized by abundant intracellular proteinaceous aggregates, including neurofibrillary tangles (NFTs). Although NAD+ and related metabolites can slow down AD progression, the effects of NAD+ on ASEs in AD remain unclear. This study investigates the relationships between NAD+ metabolism, ASEs and AD or AD-like pathologies including tauopathies using deep-learning AI-based algorithms to predict protein structures and protein-protein interactions as well as experimental tauopathy models including hTau.P301S transgenic mice and transgenic hTau[P301L] Caenorhabditis elegans. Mouse transcriptomic data were mined to detect ASEs that were differentially induced in the presence of NAD+ precursor nicotinamide riboside (NR) with specific focus on the Eva1-C locus. The results reveal that the relative abundance of Eva1-C isoforms is sensitive to both the concentration of NR and to tauopathy genotype. NAD+ abundance/metabolic status modulates ASEs and the expression of EVA1-C isoforms, which in turn regulate the interaction with the key proteins, BAG-1 and HSP70, involved in orchestrating protein homeostasis. Importantly, EVA1-C is dramatically reduced in the postmortem entorhinal cortex and hippocampal neurons from 20 Braak 5/6 AD patients compared to 20 of cognitive normal humans. Thus, this study supports the novel idea that NAD+ metabolism modulates abundance of specific mRNA isoforms, and that ASEs influence disease progression in model tauopathies and potentially AD. These results could facilitate future development of NAD+-based splice-switching therapeutics for AD.

2025-10-03 | GSE279334 | GEO

Multi-omic characterization of a soil microbial consortium reveals critical role of succinate and glutamate metabolism during calcium carbonate precipitation

Project description:Microbially induced calcium carbonate precipitation (MICP) holds potential for soil stabilization and carbon sequestration efforts. While the biogeochemical pathways and enzymes driving MICP are known, the microbial metabolic networks and community dynamics underlying such processes remain poorly characterized. To address this gap, we interrogated a MICP-capable four-member consortium of soil bacteria termed carbon storing consortium - A (CSC-A). Prior work shows that CSC-A yields carbonate at a higher quantity compared to the sum of carbonate individually produced by each member, suggesting MICP is driven by consortium dynamics.Thus, we applied a multi-omic integration approach of genomics, transcriptomics, and metabolomics to investigate potential inter-species interactions that may influence the MICP phenotype. Genomic life history characterizations identified evidence of specialization by two members, while metatranscriptomic perturbation suggested that R. qingshengii is a keystone species when grown in urea, a key molecule to the MICP process. By comparing individual species’ metabolomes to the metabolic profile of a shared well, we identified over 200 metabolites predicted to be produced or consumed by CSC-A. Integrating both data types and mapping them to the KEGG reactome highlighted over 20 different enriched pathways with reactions related to glutamate metabolism, succinate metabolism, and branched chain amino acid biosynthesis. As succinate metabolism was a major node in this network we applied laboratory assays to confirm that succinate led to increased carbonate precipitation by CSC-A, a critical validation of our modeling approach. By isolating and identifying the interconnected metabolic components underlying MICP in CSC-A, we identified keystone taxa, metabolites, and pathways important for future optimization of the application of this consortium to carbonate precipitation.

2026-02-26 | GSE320329 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data